Epic Medical Research LLC

1. Pfizer Inc. $6,114,879 151 payments
2. Amgen Inc. $911,074 3 payments
3. Moderna TX, Inc. $391,910 93 payments
4. Sanofi US Services Inc. $159,274 10 payments
5. Lexicon Pharmaceuticals, Inc. $138,388 27 payments
6. GlaxoSmithKline, LLC. $120,735 41 payments
7. Genentech, Inc. $48,447 14 payments
8. Genzyme Corporation $36,609 2 payments
9. Tolmar, Inc. $24,697 16 payments
10. Bausch Health US, LLC $20,733 5 payments

1. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $4,425,969 68 payments
2. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight $849,074 1 payment
3. A Phase 3 Master Protocol to Evaluate the Safety Tolerability and Immunogenicity of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults at High Risk of Severe RSV Disease $643,313 22 payments
4. A Phase 23 Randomized Doubleblind Doubledummy Placebo Controlled Study to Evaluate the Safety and Efficacy of 2 Regimens of Orally Administered PF 07321332Ritonavir in Preventing Symptomatic Sarscov2 Infection in Adult Household Contacts of An Individual With Symptomatic Covid19 $620,053 26 payments
5. Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age $245,034 55 payments
6. A Phase 23 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bnt162b2 Rnabased Vaccine Candidates for Sarscov2 New Variants in Healthy Individuals $226,347 17 payments
7. A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $146,876 38 payments
8. A Multicenter Randomized, Double-Blind, Placebo-Controlled Phase 2 Stu $120,735 41 payments
9. An Interventional Efficacy and Safety Phase 23 Doubleblind 2 Arm Study to Investigate Orally Administered PF 07321332Ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Low Risk of Progressing to Severe Illness $112,135 7 payments
10. A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype $82,176 6 payments

1. Patient care $50,304 8 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.